Live
Stop managing data. Start using it.

Consultancy-level intelligence, powered by live data... tailored to your business.

Boss Your Data analyses 100+ global pharmaceutical sources and filters the noise into intelligence tailored to your company: the opportunities, risks and developments that matter to you, for a fraction of what a consultancy would charge.

Scroll
The problem

The problem is not a lack of information… The problem is finding what matters.

Raw data on its own tells you nothing. It has to be gathered, connected and analysed before it means anything. Commission a consultant to do that work and the answer arrives weeks later, by which time the data it was built on is already out of date.

Too many sources.

Too much searching.

Too little meaning.

There is a better way to see the market.

Regulatory
Clinical
Patents
Products
Pricing
and 100+ more sources
The solution

We pull the market together.

See it in actionConsultancy reports

The depth of a consultancy report.
The power of live intelligence.

Turn complex life science data into clear, interactive intelligence, tailored to your priorities and updated as new evidence emerges.

ADC market story
Live01 / 05
Market intelligence · Oncology
Antibody-drug conjugates

From mechanism to market: what ADCs are, what they treat, who sells them, what they earn, what comes next and who makes them.

Antibody-drug conjugate: antibody carrying four payloads on linkers
First US approval, by year11 of 15 approved since 2019
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
'26
15
ADCs approved in the US or EU
83
More ADCs in clinical trials
$16.9bn
Est. annual sales · latest FY
285
ADC trial starts in 2026
Source: BYD_Pharma · FDA · EMA · ClinicalTrials.gov · company filings
Plays automatically · hover to pause
Built around real pharmaceutical needsCustom-made dashboards

Ask for the view you need…
Not the report someone else decided to build.

Custom dashboardTop 20 pharma by revenue, 2020–2025
Live
Top-20 revenue · 2025
$952bn
+33% since 2020
Biggest climber
Eli Lilly
▲12 places · 15th → 3rd
Biggest faller
GSK
▼6 places · Haleon demerger
Rank · 2025 revenue, US$Places moved since 2020
Eli Lilly
$65.2bnRevenue 2025
15 → 3Rank 2020 → 2025
202020212022202320242025
Biggest sellers · Mounjaro, ZepboundTirzepatide for diabetes and obesity drove the biggest climb in the top 20; Verzenio (breast cancer) is the next largest.
Source: BYD_Pharma company financials · FY total revenue, US$ · data as of 1 Nov 2026

Tell us the decisions your team makes each week. We build the dashboard around them, using your markets, molecules, competitors and sites, and keep it live across 100+ sources so the view updates as the evidence does.

MCP connection

Ask in the assistant you already use.

One MCP connection lets Claude, ChatGPT or your internal agent pull straight from 100+ pharmaceutical sources. Ask in plain language, get structured evidence back.

No exports, no new dashboard to learn.
The model reads the data; you read the answer.
Every figure carries its source and capture date.
How many Phase III NSCLC trials started this year, and who is running them?
Boss Your Data · MCPQuerying openFDA · EDGAR · CT.gov…
47 Phase III starts so far this year, against 31 over the same period last year. Four sponsors account for a third of them.
Phase III NSCLC startsYTD · sponsors
Large pharma19
Mid-cap14
Biotech9
Academic5
ClinicalTrials.gov · captured 18 May
Select an assistant above

See what we'd build for you!

Boss Your Data News · Free

Start with the free news app.

Boss Your Data News brings together content from 50+ pharmaceutical and life science news and regulatory sources. Follow the industry without having to visit dozens of websites.

One place to keep up with pharma. No subscription required.

Download the free app
Boss Your Data News — daily briefing, 24 hoursDaily briefing, 7 days
News feed
News feed behind the filter
FILTER BY TOPIC
Topics & event types
General news
Regulatory
Clinical trials
1
Results posted
Trial started
Enrolment complete
Status change
Terminated
Deals & M&A
Manufacturing
Financials
Clear
Done
Daily briefing · 24 hours